Target intelligence / Profile preview

Neuraminidase (Influenza A virus subtype H5N1) (NA)

Target
NA
Molecular classification
Enzyme, Glycosyl hydrolase family 34, Viral surface glycoprotein
01

Overview

H5N1 neuraminidase is a critical surface enzyme of the Highly Pathogenic Avian Influenza A (H5N1) virus, belonging to the glycosyl hydrolase family 34 (UniProt: P0C6Y6). Its primary biological role is to catalyze the hydrolysis of terminal sialic acid residues from host cell receptors and viral glycoproteins, a process essential for the release of newly formed virions from the host cell membrane and preventing viral aggregation. By facilitating viral spread throughout the respiratory tract and aiding in the penetration of the mucus layer, it plays a central role in the pathogenesis of avian influenza (NIH: NBK11771). This enzyme is the primary target for the neuraminidase inhibitor (NAI) class of antiviral drugs, including oseltamivir and zanamivir, which competitively bind to the conserved active site to arrest viral replication (StatPearls: NBK539909). However, the clinical utility of these drugs is threatened by the emergence of specific amino acid substitutions, such as the H274Y mutation, which significantly reduce drug sensitivity and complicate pandemic preparedness efforts. Understanding the structural dynamics of this protein is vital for the development of next-generation antivirals that can overcome existing resistance mechanisms.

Other names
SialidaseExo-alpha-sialidaseN1 neuraminidaseH5N1 NANeuraminidase (NA)
02

Mechanism of action

Neuraminidase inhibitors competitively bind to the enzyme's highly conserved active site, preventing the cleavage of terminal sialic acid residues on host cell receptors and viral glycoproteins, which traps progeny virions on the cell surface and halts the spread of infection.

03

Biological functions

Viral releaseViral disseminationCleavage of terminal sialic acidMucus penetrationPrevention of viral aggregation
04

Disease associations

InfectionAvian influenzaInfluenza A
05

Safety considerations

Emergence of antiviral resistance (e.g., H274Y mutation)Neuropsychiatric events (associated with oseltamivir)Gastrointestinal distressNarrow therapeutic window (efficacy decreases after 48 hours of symptom onset)
06

Interacting drugs

3 more in the full profile.

07

Biomarkers

Viral RNA loadNeuraminidase inhibition (NAI) assayH274Y mutation statusN151D mutation status

Source types: Peer-reviewed publication. Sources are available to Gosset users. Log in to see them.

Beyond the preview

Go deeper on Neuraminidase (Influenza A virus subtype H5N1) (NA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neuraminidase (Influenza A virus subtype H5N1) (NA).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call